Screening for Pancreatic Exocrine Insufficieny in Metabolic Associated Fatty Liver Disease Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-30

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

to investigate the frequency of PEI in MAFLD

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fatty Liver and Pancreatic Steatosis

NCT06757348

Exocrine Pancreatic Insufficiency Fatty Liver, Nonalcoholic Pancreatic Steatosis

NOT_YET_RECRUITING

HOMA-IR as a Screening Test in NAFLD

NCT04084925

NAFLD

COMPLETED

Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis

NCT03386890

Nonalcoholic Fatty Liver Disease Liver Steatosis Liver Fibrosis

UNKNOWN

Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome

NCT00399932

Metabolic Syndrome

UNKNOWN

Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER

NCT04165343

Non-Alcoholic Fatty Liver Disease (NAFLD) Nonalcoholic Steatohepatitis (NASH)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The growing epidemic of obesity is observed worldwide as lifestyles change to include higher caloric diets and decreasing physical activity.

With obesity; ectopic fat deposition in certain organs is accompanied by insulin resistance, hypertension and dyslipidemia; which in turn leads to metabolic syndrome As such, metabolic associated fatty liver disease (MAFLD), the hepatic manifestation of metabolic syndrome, has already become the most common cause of liver disease worldwide with a prevalence 25% Another important organ where ectopic fat deposition takes place is pancreas. Although hepatic fat is mainly intracellular and fatty pancreas is a consequence of adipocyte infiltration, evidence exists that fatty pancreas could be used as the initial indicator of ectopic fat deposition Recently, an advanced MRI technique - MRI-estimated proton density fat fraction (MRI-PDFF) - was shown to give reliable quantitative information of hepatic fat that is well correlated with liver biopsy The pancreas is composed of two glands - endocrine pancreas and exocrine pancreas- that are intimately mixed together into one organ Although exocrine pancreas comprise more than 95% of the pancreatic mass, to date there is no study conducted about the exocrine pancreas function and pancreatic fat in MAFLD patients The fecal pancreatic elastase (PE) test is a valuable indirect assay used in the evaluation of pancreatic exocrine function PE testing has become a standard diagnostic tool exhibiting good correlation with the results of direct functional tests as well as morphological changes in the pancreas discovered via imaging techniques In the last decade, significant number of studies were conducted on pancreatic exocrine insufficiency (PEI)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Exocrine Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FECAL ELASTASE

screening for pancreatic exocrine insufficiency in MAFLD patients

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than 18 years, Patients diagnosed as MAFLD

Exclusion Criteria

* Patients use steatogenic medications, hormone replacement therapy or herbal products, any alcohol intake.

* Patients with any history of pancreatic diseases like acute pancreatitis, chronic pancreatitis and pancreatic surgery.
* Patients with any malignancy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No